OM
KURA icon

Opaleye Management’s Kura Oncology KURA Stock Holding History

Opaleye Management’s Portfolio KURA Stock Details KURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-25,200
Closed -$418K – 50
2019
Q1 		$418K Buy
+25,200
New +$388K 0.12% 51

Other funds holding KURA

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
CTA
Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Opaleye Management's KURA Position: Q2 2019 in Review

Opaleye Management sold out of Kura Oncology (KURA) in Q2 2019, closing a stake of 25,200 shares — an estimated $418K sold.

Opaleye Management first reported a position in KURA in Q1 2019 and held it in 1 quarter. The position peaked at $418K in Q1 2019. 122 funds tracked by Wall St. Rank hold KURA as of Q2 2019.

  • Opaleye Management reported no remaining Kura Oncology position as of Q2 2019 after selling out during the quarter.
  • Opaleye Management sold 25,200 Kura Oncology shares in Q2 2019, an estimated $418K.
  • Opaleye Management first reported a position in Kura Oncology in Q1 2019 and held it in 1 quarter.
  • Opaleye Management's Kura Oncology position peaked at $418K in Q1 2019.
  • 122 funds tracked by Wall St. Rank held Kura Oncology as of Q2 2019.

Based on Opaleye Management's 13F filing for Q2 2019, filed 14 Aug 2019.